Acad to present Ph 2 results on Tuesday of Pimavanserin in MDD. They look quite good to me. Ph 3 initiated last month. Is the FDA approval process likely to be more streamlined to add MDD to the label for an already approved drug? ... or it makes no difference?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.